Bringing Clarity to Clozaril®

You have tried conventional antipsychotic drugs on your patient with schizophrenia, but he or she is either unable to achieve a satisfactory clinical response or there are dose-limiting, intolerable adverse effects – now what? Non-responsiveness is defined as the lack of satisfactory clinical response, despite treatment with appropriate courses of at least two marketed chemically unrelated antipsychotic drugs. Intolerance is defined as the inability to achieve adequate benefit with conventional antipsychotic drugs because of dose-limiting, intolerable adverse effects.

Clozaril® (clozapine) is indicated in the management of symptoms of treatment-resistant schizophrenia1. In controlled clinical trials, clozapine was found to improve both positive and negative symptoms.

Please see the videos for more information regarding:

  • Clozaril® therapy
  • Treatment-resistant schizophrenia
  • Clozaril® Support and Assistance Network (CSAN®)
  • CSAN Patient Care Portal®

For more information:

Please consult the Product Monograph for important information relating to contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use.


  1. Clozaril® Product Monograph. HLS Therapeutics Inc., May 31, 2022.
For Canadian Residents Only | Français


Working with the patient on Clozaril®

Play Video

Prescribing considerations
Read important prescribing information to see if Clozaril® is appropriate for your patient

Clozaril® Product

Clozaril® HCP Brochure

Hematological quick reference chart

Schizophrenia Disease Progression Tool

CSAN® Quick Reference Tool

Discover the CSAN Patient Care Portal®

Clozaril® Patient Booklet